v3.20.4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Cash Flows From Operating Activities    
Net loss $ (18,308) $ (16,077)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 4,102 3,164
Interest accretion 414 331
Reversal of 2019 bonus accrual (1,156)
Mark to market on warrants (62) (35)
Stock-based compensation 1,381 1,246
Bad debt expense 250 499
Other gains and expenses, net 18
Other changes in operating assets and liabilities:    
Decrease (increase) in accounts receivable 1,625 (1,986)
Increase in other current assets (898) (417)
Increase in long-term assets (11)
Decrease in accounts payable (1,319) (766)
Increase in accrued salaries and bonus 129 108
Increase in accrued liabilities 1,472 924
(Decrease) increase in long-term liabilities (25) 446
Net cash used in operating activities (12,395) (12,556)
Cash Flows From Investing Activity    
Acquisition of Biopharma, net of expenses (13,829)
Purchase of property and equipment (1,275) (105)
Sale of property and equipment 13
Net cash used in investing activities (1,275) (13,921)
Cash Flows From Financing Activities    
Issuance of common stock, net of expenses 434 5,962
Issuance of preferred shares, net of expenses 13,087
(Payments) borrowings on Line of Credit, net (3,000) 3,750
Issuance of Series B preferred stock, net of expenses 19,223
Cash paid for repurchase of restricted shares (32)
Net cash provided by financing activities 16,657 22,767
Net increase (decrease) in cash and cash equivalents 2,987 (3,710)
Cash and cash equivalents - beginning 2,321 6,068
Cash and cash equivalents - ending $ 5,308 $ 2,358

Source